Document Detail


Immunotherapy in the treatment of advanced prostate cancer.
MedLine Citation:
PMID:  22018147     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Prostate cancer is a complex disease, and treatment selection is informed by numerous variables depending on the stage of disease. Moreover, patient expectations and the impact of treatment-related adverse events may influence treatment choices. Available treatment options over the course of the disease have included surgery, radiation therapy, hormonal therapy, immunotherapy, and chemotherapy. This complexity requires an understanding of a wide range of treatment options and the support of a multidisciplinary team that involves urologists, radiation oncologists, diagnostic radiologists, pathologists, and medical oncologists. Collaboration among these physicians allows for a comprehensive treatment strategy that addresses the individual needs of the patient throughout the course of his disease. Prior to 2004, treatment options for metastatic castrate-resistant prostate cancer (CRPC) were limited to therapies for palliation of pain and reduction of skeletal-related events. Over the past 7 years, four therapeutic options-three within the last 2 years-that provide a survival benefit in this setting have been approved. These therapies have diverse mechanisms, perhaps reflecting the complex nature of advanced prostate cancer. Among them is sipuleucel-T, the first autologous immunotherapy approved for any cancer. This review will discuss the rapidly changing treatment environment for metastatic CRPC and the increased exploration of immunotherapeutic approaches to advanced prostate cancer.
Authors:
Bob Djavan; Kathleen Nelson; Amir Kazzazi; Aron Bruhn; Helen Sadri; Alejandro Gomez-Pinillos; Anna C Ferrari
Related Documents :
21620777 - Cell autonomous role of pten in regulating castration-resistant prostate cancer growth.
22198737 - Validation of prostate cancer risk-related loci identified from genome-wide association...
1283387 - Relationship between interphase agnor distribution and nucleolar size in cancer cells.
6265707 - Herpes simplex type 2 neutralization antibodies in patients with cancers of urinary bla...
17113217 - Implications of prostate-specific antigen doubling time as indicator of failure after s...
23294467 - Potential use of drug loaded nano composite pectin scaffolds for the treatment of ovari...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Canadian journal of urology     Volume:  18     ISSN:  1195-9479     ISO Abbreviation:  Can J Urol     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9515842     Medline TA:  Can J Urol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  5865-74     Citation Subset:  IM    
Affiliation:
Department of Urology, New York University School of Medicine, NYU, New York, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Food supplements increase adult tarsus length, but not growth rate, in an island population of house...
Next Document:  Screening for prostate cancer 2011: the current evidence and guidelines controversy.